In the biopharmaceutical industry, there has been a shift away from on-site construction to prefabricated solutions. Peter Makowenskyj, Director of Sales Engineering at G-CON Manufacturing Inc., recently told Pharmaceutical Technology that speed to market and lower total cost of ownership for facilities has accelerated this movement in the biopharma sector. He also discussed the strain that the COVID-19 pandemic has placed on operations across the industry and how the situation is creating a need for additional capacity.
